Regeneron Pharmaceuticals
REGN
1,091.19
USD
13.14
(1.22%)
مغلق
حجم التداول
45,513
الربح لكل سهم
0
العائد الربحي
0
P/E
26
حجم السوق
106,775,369,480
أصول ذات صلة
الأخبار
المقالات
العنوان: Regeneron Pharmaceuticals
القطاع: Healthcare
الصناعة: Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).